Corcept announces publication of analysis of Phase 2 trial of relacorilant

Corcept Therapeutics announced publication of the final analysis from its Phase 2 trial evaluating its proprietary cortisol modulator, relacorilant, in women with platinum-resistant ovarian cancer in the Journal of Clinical Oncology, the premiere journal of the American Society of Clinical Oncology. In the trial, patients who received relacorilant orally the day before, the day of and the day after their nab-paclitaxel infusion experienced a 34 percent reduction in risk of disease progression, responded to treatment longer and had a 33 percent reduction in risk of death compared to patients who received nab-paclitaxel alone. Adverse events were comparable across the study arms. PFS and OS benefits were exhibited across multiple subgroups of patients. Patients who would have met the eligibility requirements for Corcept’s confirmatory Phase 3 ROSELLA trial did especially well. A post-hoc analysis showed that patients who had received prior bevacizumab, did not have primary platinum-refractory disease and who had received no more than three prior lines of therapy experienced a 62 percent reduction in risk of death compared to similar patients who received nab-paclitaxel alone.